e-ISSN: 2722-9807

Sriwijaya Journal of Ophthalmology

[SJO]

https://sriwijayaophthalmology.com

Navigating Therapeutic Challenges in Adult-Onset Coats' Disease: Successful Vitrectomy for Tractional Retinal Detachment Following Laser Photocoagulation

Albatool Alqahtani[1*], Faisal Al-Qahtani[2], Abdullah Al Hilali[2], Alwaleed Alsulaiman[2]

[1]King Khalid University, Abha, Kingdom of Saudi Arabia

[2]King Khaled Eye Specialist Hospital, Riyadh, Kingdom of Saudi Arabia

ARTICLE INFO

Keywords:
Adult-onset Coats' disease
Laser photocoagulation
Pars plana vitrectomy
Tractional retinal detachment
Vitreoretinal surgery

***Corresponding author:**
Albatool Alqahtani

E-mail address:
albatoolm99@gmail.com

All authors have reviewed and approved the final version of the manuscript.

https://doi.org/10.37275/sjo.v8i1.131

A B S T R A C T

Introduction: Adult-onset Coats' disease, an infrequent variant of idiopathic exudative retinopathy, presents a unique management paradigm. While laser photocoagulation is a primary treatment for the characteristic retinal telangiectasia, it can paradoxically trigger a severe inflammatory and fibrotic cascade, leading to vision-threatening complications. This report addresses a critical clinical question: What is the optimal management strategy when first-line ablative therapy not only fails but leads to iatrogenic tractional retinal detachment? **Case presentation:** A 35-year-old male presented with a 15-day history of metamorphopsia in his right eye. Best-corrected visual acuity (BCVA) was 20/20. Multimodal imaging confirmed Stage 2B Coats' disease. Following sectoral argon laser photocoagulation, his BCVA declined to a nadir of 20/60. Within two months of laser, optical coherence tomography (OCT) documented the rapid development of an epiretinal membrane and a subsequent superior macular tractional retinal detachment (TRD). A 23-gauge pars plana vitrectomy (PPV) with membrane peeling was performed. Anatomical success was achieved, and at the six-month follow-up, the retina remained attached, and BCVA improved to 20/40. **Conclusion:** This case demonstrates that laser-induced inflammation can rapidly convert an exudative process into a complex fibro-proliferative state in adult-onset Coats' disease. When confronted with iatrogenic fibrosis, medical management is insufficient. This report validates that timely and definitive surgical intervention with PPV is not merely an option but an essential strategy for reversing the disease trajectory, achieving anatomical restoration, and salvaging vision.

1. Introduction

Coats' disease, first elucidated by Scottish ophthalmologist George Coats in 1908, remains a challenging and enigmatic entity defined by idiopathic retinal telangiectasia, aneurysmal vascular dilatations, and progressive intraretinal and subretinal exudation.[1] The fundamental pathology is a primary vasculopathy, leading to a breakdown of the blood-retinal barrier (BRB) and chronic plasma leakage.[2] If left unchecked, this process can culminate in total exudative retinal detachment, neovascular glaucoma, and ultimately, a blind and painful eye (phthisis bulbi). The disease has a strong predilection for young males, with an estimated 85% of cases diagnosed in the first decade of life.[3] In stark contrast, adult-onset Coats' disease, with a diagnostic age threshold typically set after 30 years, is a clinical rarity with an estimated incidence of less than 0.1 per 100,000. Its clinical course often diverges from the aggressive trajectory seen in children, typically manifesting as a more localized, indolent vasculopathy with a correspondingly better visual prognosis.[4] However, this subtlety can make diagnosis challenging, as its presentation can mimic other, more common posterior segment pathologies in adults. The differential diagnosis is broad, encompassing conditions like branch retinal vein occlusion, diabetic retinopathy, retinal vasculitis, ocular ischemic syndrome, and various forms of macular telangiectasia, all of which can present with vascular leakage and exudation.[5]

The management of Coats' disease is predicated on ablating the incompetent retinal vasculature to halt exudation.[6] For localized disease (Shields Stages 2 and 3A), ablative therapies—laser photocoagulation for posterior lesions and cryotherapy for more peripheral ones—are the established first-line treatments. However, these interventions are not benign. By inducing a controlled thermal injury, they initiate a complex wound-healing response. In most cases, this response is therapeutic, leading to vascular closure and chorioretinal adhesion. In a subset of patients, however, this response can become dysregulated, paradoxically inciting a fulminant inflammatory and fibrotic cascade that can worsen the clinical picture. The development of a tractional retinal detachment (TRD) is an uncommon but severe complication of Coats' disease, signaling a fundamental shift from a purely exudative to a fibro-proliferative pathophysiology.[7] This evolution is typically associated with chronic, organized exudates but can be acutely precipitated by the inflammatory stimulus of ablative therapy. The management of an established TRD is invariably surgical, requiring advanced pars plana vitrectomy (PPV) to mechanically relieve the tractional forces.[8]

This case report addresses a critical clinical question: What is the optimal management strategy when first-line ablative therapy for adult-onset Coats' disease not only fails but leads to vision-threatening fibrotic complications? The novelty of this report lies in its detailed, multimodally-imaged documentation of this rare and rapid iatrogenic sequence: the development of a vision-threatening TRD directly following standard-of-care laser photocoagulation. While post-treatment complications are acknowledged in the literature, a granular account of this specific adverse therapeutic pathway in the adult-onset form is lacking.[9,10] Therefore, this study aims to fill a critical gap by meticulously describing the clinical course, diagnostic challenges, and successful surgical management of this complex case. By doing so, we intend to highlight the potential pitfalls of ablative therapy, provide a robust discussion of the underlying cellular mechanisms that drive such a paradoxical response, and underscore the critical role of timely vitreoretinal surgery in navigating these therapeutic challenges to preserve vision.

2. Case Presentation

A 35-year-old male engineer, with no significant past medical or ocular history, presented to the emergency department of King Khaled Eye Specialist Hospital. He reported a 15-day history of gradually worsening metamorphopsia, described as "wavy and distorted lines," and a subtle, subjective blur in his right eye (oculus dexter, OD). He denied any perception of a scotoma, floaters, photopsia, or pain. On initial examination, the patient's clinical status was thoroughly evaluated. Despite his symptoms, his best-corrected visual acuity (BCVA) was an excellent 20/20 in both eyes (oculus uterque, OU). Intraocular pressures were normal. The anterior segment examination of the right eye was notable only for a very mild, low-grade inflammatory reaction, with +0.5 cells in the anterior chamber but no flare. This finding was considered likely a secondary inflammatory spillover from the significant posterior segment pathology rather than indicative of a primary uveitic entity, given the absence of other inflammatory signs like keratic precipitates or posterior synechiae. The comprehensive initial assessment is detailed in Figure 1. The dilated fundus examination of the right eye revealed the full extent of the pathology. A large, well-demarcated zone of dense, yellow, lipid-rich subretinal exudation was present, centered in the infero-temporal quadrant. It extended from the vascular arcade posteriorly to the equator anteriorly, spanning approximately four clock hours from 7 o'clock to 11 o'clock. At the posterior border of this exudative area, a cluster of prominent, tortuous, and irregularly dilated telangiectatic vessels was clearly visible, exhibiting characteristic saccular and "light-bulb" shaped aneurysmal dilatations. A small, linear pre-retinal hemorrhage was noted superior to this vascular anomaly. Dispersed throughout the vitreous, particularly overlying the temporal retina, were innumerable glistening, refractile cholesterol crystals (cholesterolosis), a hallmark of chronic vascular leakage. Critically, the macula and optic disc appeared uninvolved and healthy at this initial presentation (Figure 1A).



Figure 1. Summary of initial findings at presentation. A: Color fundus photo shows extensive, yellow subretinal exudation in the temporal quadrant with overlying vitreous cholesterolosis. B: Fluorescein angiogram reveals prominent telangiectatic vessels with "light-bulb" aneurysms showing profuse late-phase leakage. C: Fundus photo one month post-laser shows exacerbation of subretinal exudation and increased vitreous haze. D: OCT scan confirms the development of an epiretinal membrane with cystoid macular edema and traction.

A complete diagnostic workup with multimodal imaging was performed to confirm the diagnosis and guide treatment, as summarized in Figure 2. Fundus fluorescein angiography (FFA) provided a dynamic view of the vascular incompetence. The arteriovenous transit time was normal. Early phase frames at 25 seconds revealed rapid, preferential filling of the dilated telangiectatic vessels. Profuse, intense leakage from these vessels became apparent by 45 seconds (mid-phase), leading to significant late-phase staining of the surrounding retinal tissue and pooling of dye in the subretinal space, unequivocally identifying these vessels as the source of the exudation. No areas of capillary non-perfusion were noted. The dense lipid exudate caused a corresponding area of blocked fluorescence (Figure 1B). High-resolution spectral-domain optical coherence tomography (OCT) of the macula was performed to assess its structural integrity. The scans confirmed the absence of foveal involvement. A detailed layer-by-layer analysis showed a preserved foveal contour with all retinal layers, most importantly the ellipsoid zone (EZ) and external limiting membrane (ELM), appearing intact and continuous. This finding established an excellent baseline of photoreceptor integrity and a high potential for visual recovery. Based on this constellation of findings, a diagnosis of adult-onset Coats' disease, Shields Stage 2B, was made.

Summary of Diagnostic Imaging Findings

Schematic representation of Fundus Fluorescein Angiography (FFA) and Optical Coherence Tomography (OCT) at baseline.

Fundus Fluorescein Angiography (FFA)



Optical Coherence Tomography (OCT)



Diagnostic Summary

FFA Findings

- Vascular Leakage:Profuse, late-phase hyperfluorescence from temporal telangiectatic vessels.
- Aneurysms:Multiple hyperfluorescent "light-bulb" aneurysms confirming vascular incompetence.
- Blocked Fluorescence:Hypofluorescent area corresponding to the dense lipid exudation.

OCT Findings

- Macular Status:Uninvolved. No evidence of subretinal fluid, cystoid edema, or epiretinal membrane.
- Retinal Layers:Preserved foveal contour with intact and continuous Ellipsoid Zone (EZ) and ELM bands.
- CMT:Normal central macular thickness of 255μm, indicating high potential for visual recovery.

Figure 2. Summary of diagnosis imaging findings.

Development of Tractional Retinal Detachment

Clinical and schematic representation of the vision-threatening complication at 2-months post-laser.



Pathological Summary

- ⚠ Fundus Findings (A): A fibrotic band is now visible, extending from the temporal periphery. The retina appears elevated and distorted, with increased haze obscuring details, consistent with a developing TRD.
- ⚠ OCT Confirmation (B):The scan provides definitive evidence, showing a hyperreflective epiretinal membrane on the retinal surface exerting powerful tangential forces.
- ⚠ Mechanism of Detachment:The membrane is physically pulling the retinal layers inward and upward, creating a "tent-like" elevation and separating them from the underlying RPE.
- ⚠ Threat to Vision:The detachment is clearly shown to be involving the superior macula and is actively progressing towards the foveal center, representing an urgent threat to central vision and necessitating surgical intervention.

Figure 3. Clinical and schematic representation of the vision-threatening complication at 2 months post-laser. fundus findings (A): A fibrotic band is now visible, extending from the temporal periphery. The retina appears elevated and distorted, with increased haze obscuring details, consistent with a developing TRD. OCT Confirmation (B): The scan provides definitive evidence, showing a hyperreflective epiretinal membrane on the retinal surface exerting powerful tangential forces.

After a thorough discussion with the patient regarding the diagnosis, prognosis, and treatment options, including the risks of intervention (such as post-treatment inflammation) versus the risks of observation (such as progressive exudation and vision loss), a decision was made to proceed with ablative therapy. The patient underwent argon green laser photocoagulation. The power was titrated to achieve a gentle, opaque whitening of the retina, indicating sufficient coagulation of the target vessels. A total of 215 spots (150 μm spot size, 0.15s duration, 220 mW power) were applied directly to and surrounding the leaking telangiectatic vessels. The post-treatment course, however, was marked by a rapid and paradoxical deterioration, as detailed in Figure 4. One month after the procedure, the patient's BCVA had plummeted from 20/20 to 20/60 OD. Fundus examination revealed a dramatic increase in the volume and turbidity of the subretinal exudate and a worsening of the vitreous cholesterolosis. The OCT at this visit was alarming: it showed a newly formed, hyperreflective band on the inner retinal surface consistent with an epiretinal membrane (ERM), causing clear tractional distortion of the inner retinal layers and the development of intraretinal hyporeflective cystoid spaces (Figure 1C, 1D). By the two-month follow-up, the clinical situation had evolved into a surgical emergency. A distinct fibrotic band was now visible, extending from the lasered temporal periphery towards the macula. The OCT confirmed a taut ERM exerting significant tangential traction, resulting in a tent-like elevation of the superior macular retina off the RPE, with a clear pocket of subretinal fluid. This confirmed a progressive TRD that was now encroaching upon the foveal center (Figure 3A, 3B).

With a progressive, vision-threatening TRD, surgical intervention was imperative. The patient underwent a 23-gauge three-port pars plana vitrectomy (PPV) using the Alcon Constellation Vision System. A detailed narrative of the procedure and outcomes is provided in Figure 6. During the surgery, a core vitrectomy was performed, clearing the dense vitreous cholesterolosis. Induction of a posterior vitreous detachment (PVD) was initiated at the optic disc and was challenging due to strong vitreopapillary adhesions, but was eventually completed to the periphery. The ERM was stained with Brilliant Blue G dye, revealing its full extent over the macula. It was engaged at its edge with end-gripping forceps and meticulously peeled in a single sheet. The underlying ILM was then re-stained and peeled in a circumferential manner to approximately two-disc diameters around the fovea, ensuring the complete removal of any scaffold for future cellular proliferation. Peripheral cryotherapy was then applied under direct visualization to the original site of the temporal vascular abnormalities. At the conclusion of the case, a fluid-air exchange confirmed that the retina was fully attached and all traction had been relieved, obviating the need for a tamponade agent. The post-operative course was excellent. At the six-month follow-up, the patient's BCVA had recovered to 20/40, and the retina remained stable and attached, with ongoing, slow consolidation of the peripheral exudates (Figure 5A, 5B).



Figure 4. Timeline of treatment and complication development.



Figure 5. Post-operative outcome after vitrectomy. anatomical success (A): The fundus is dramatically improved. The macula is flat, and the temporal exudation is significantly reduced and consolidated. The vitreous is clear. Macular Restoration (B): The post-operative OCT confirms a complete resolution of the tractional detachment. The retinal layers are re-apposed to the RPE.

3. Discussion

This case report details the dramatic and rapid transformation of a relatively quiescent, extrafoveal adult-onset Coats' disease into a vision-threatening surgical emergency following standard-of-care laser photocoagulation.[11] The clinical journey of this patient—from excellent baseline vision to an iatrogenically-triggered tractional retinal detachment and subsequent successful surgical salvage—provides a unique window into the complex pathophysiology of the disease, the profound biological consequences of retinal laser therapy, and the critical decision-making required in modern vitreoretinal surgery. This discussion dissects the case through three lenses: the unique pathophysiology of adult-onset Coats' disease, a deep molecular analysis of the "laser paradox," and a critical evaluation of the management pathway. The cornerstone of Coats' disease pathology, regardless of age, is a primary, non-inflammatory vasculopathy rooted in the structural failure of the retinal vasculature.[12] Histopathological studies have consistently identified the fundamental lesion as a profound deficiency or complete absence of pericytes, the mural cells that encircle retinal capillaries and are indispensable for their structural integrity and autoregulatory function.[13] This pericyte loss, coupled with a thinning of the vascular endothelial basement membrane, leads to the formation of the characteristic telangiectasias and saccular "light-bulb" aneurysms. These vessels are functionally incompetent, resulting in a chronic, progressive breakdown of the inner blood-retinal barrier (BRB), which is formed by the tight junctions between retinal capillary endothelial cells.[14] This breakdown allows for the unchecked extravasation of blood plasma constituents—water, electrolytes, proteins, and lipids—into the retinal interstitium and the subretinal space. The accumulation of this lipid-rich fluid constitutes the hallmark yellow exudates of Coats' disease.[15] Over time, these lipids are phagocytosed by macrophages, which become engorged with lipid droplets ("foam cells") and contribute to a low-grade, chronic inflammatory milieu. The crystalline cholesterol deposits observed in the vitreous and subretinal space are the end-product of the breakdown of these lipoproteins by macrophages, a pathognomonic sign of the chronicity and severity of the vascular leakage.[16]



Figure 6. Summary of surgical intervention and post-operative outcomes.

While the "what" of the pathology is clear, the "why" remains elusive, particularly in the adult-onset form. In pediatric cases, somatic mutations in the NDP gene, located on the X chromosome and encoding the protein Norrin, have been implicated. Norrin is a critical ligand in the canonical Wnt/β-catenin signaling pathway, a highly conserved pathway that is essential for normal retinal vascular development, stabilization, and maturation.[17] Norrin, secreted by Müller cells, binds to its receptor Frizzled-4 (FZD4) on endothelial cells, activating the Wnt pathway, which in turn promotes the recruitment of pericytes and the formation of robust tight junctions, thus solidifying the BRB. A loss-of-function mutation in NDP can disrupt this pathway, leading to the widespread vascular abnormalities and severe exudation seen in children.[18] In adults, the etiology is likely more heterogeneous and complex. It may represent a forme fruste of the same genetic defect with lower penetrance or a later somatic "second-hit" mutation. Alternatively, it could be an entirely different acquired process—a localized, degenerative microangiopathy or a low-grade, chronic inflammatory process that selectively targets and destroys pericytes over time. The presence of a mild anterior chamber reaction in our patient, even at baseline, lends credence to the idea that an underlying, subclinical inflammatory state may exist even in seemingly quiescent cases.[17] This pre-existing inflammation, however subtle, may sensitize the eye to further insult, creating a "tinderbox" environment that can be ignited by a significant inflammatory trigger like laser photocoagulation. The clinical phenotype of adult-onset Coats' disease, typically more localized and indolent than its pediatric counterpart, likely reflects a more focal and less severe degree of pericyte loss. This allows for large areas of the retinal vasculature to remain competent, thereby confining the exudative process and often leading to a better overall prognosis. However, as this case powerfully demonstrates, even a localized pathology exists in a delicate and precarious equilibrium, one that can be catastrophically and rapidly disrupted by a therapeutic intervention.

The central, most instructive element of this case is the paradoxical response to laser photocoagulation. Instead of promoting resolution by ablating leaking vessels, the laser acted as a potent catalyst, converting a chronic, contained exudative state into an acute, explosive fibro-proliferative crisis. This phenomenon, the "laser paradox," can be understood as a dysregulated and exaggerated wound-healing response, driven by a complex and self-amplifying interplay of inflammatory cytokines, activated retinal cells, and the extracellular matrix.[18] Argon laser photocoagulation achieves its therapeutic effect through the precise delivery of thermal energy. The absorption of this energy by melanin in the retinal pigment epithelium (RPE) and choroid generates intense, localized heat, causing coagulative necrosis of the targeted vessels and the surrounding retinal tissue. This acute, controlled burn, while therapeutic in intent, is a profound biological insult that unleashes a powerful and immediate wound-healing response. Damaged and necrotic cells release their intracellular contents, including a host of molecules known as damage-associated molecular patterns (DAMPs), such as high-mobility group box 1 (HMGB1) and ATP. These DAMPs are potent activators of the innate immune system, binding to Toll-like receptors (TLRs) on resident retinal cells like microglia and Müller cells, triggering an immediate and intense inflammatory cascade—a veritable "cytokine storm" within the delicate microenvironment of the retina.[18] Within hours of the laser application, there is a massive upregulation of pro-inflammatory cytokines. These include tumor necrosis factor-alpha (TNF-α) and Interleukin-1β (IL-1β), which are considered master regulators of inflammation. They act on the retinal vasculature to dramatically increase permeability and promote the expression of adhesion molecules, such as ICAM-1, on endothelial cells. This "activates" the endothelium, facilitating the recruitment and extravasation of leukocytes from the bloodstream. Concurrently, a flood of chemokines, including monocyte chemoattractant protein-1 (MCP-1) and Interleukin-8 (IL-8), is released, creating a powerful chemical gradient that actively draws macrophages and neutrophils to the site of injury. These recruited inflammatory cells, in turn, release their own cocktail of cytokines, proteases, and reactive oxygen species, further amplifying the inflammatory cascade. Vascular endothelial growth factor (VEGF), a key pathogenic molecule in Coats' disease to begin with, is also strongly and rapidly upregulated by the hypoxia and inflammation induced by the laser burn.[19] The immediate effect of this cytokine surge is a dramatic increase in vascular leakage, not just from the originally incompetent telangiectasias but also from adjacent, previously stable capillaries. This mechanism provides a clear molecular explanation for the marked increase in subretinal exudation and macular edema observed in our patient one month after treatment. The therapeutic burn, intended to seal leaks, had instead opened the floodgates.

This intense inflammatory environment is the critical signal that activates the key cellular players responsible for fibrosis and membrane formation: the Müller glial cells and the retinal pigment epithelium (RPE).[19] This activation represents the "fibrotic switch," the point at which the process transitions from inflammation and exudation to proliferation and contraction. Müller Cells, As the principal structural and homeostatic glial cells of the retina, Müller cells span the entire retinal thickness and are exquisitely sensitive to any form of retinal injury. In response to the cytokine storm, particularly to the potent pro-fibrotic molecule Transforming Growth Factor-beta (TGF-β), they undergo a process known as reactive gliosis. This is not merely a passive scarring process. The Müller cells become hypertrophic, proliferative, and begin to migrate. Most importantly, they undergo a myofibroblastic transdifferentiation, a remarkable cellular transformation where they begin to express α-smooth muscle actin (α-SMA), the same contractile protein found in smooth muscle cells. This endows them with powerful contractile properties. They also switch their metabolic machinery from a supportive role to a pro-fibrotic one, massively upregulating their synthesis and secretion of extracellular matrix (ECM) proteins, such as collagen types I and III, and fibronectin. The RPE, being directly in the line of fire of the laser burn, is another major contributor to the fibrotic response. Injured RPE cells can undergo a well-described process called epithelial-mesenchymal transition (EMT).[19] In EMT, the RPE cells lose their characteristic hexagonal, cobblestone epithelial morphology and their tight junctions, and acquire a migratory, spindle-shaped, fibroblast-like phenotype. This transition is also driven by TGF-β. Like the activated Müller cells, these transformed RPE cells also produce contractile proteins and large quantities of abnormal ECM. These activated and transformed cells—myofibroblastic Müller cells and mesenchymal RPE cells—migrate onto the retinal surface, using the internal limiting membrane (ILM), which is the basement membrane of the Müller cells, as a natural and ideal scaffold. They proliferate and deposit layers of this new, abnormal, collagen-rich ECM, forming the avascular, contractile sheet that is the epiretinal membrane (ERM). The contraction of this membrane, driven by the collective, synchronized force of its millions of myofibroblastic cellular components, exerts powerful tangential traction on the surface of the retina. This force is what causes the retinal wrinkling, the distortion of the macular architecture, and ultimately, the inward pulling and tent-like elevation of the retina that constitutes a tractional retinal detachment. In our patient, this entire, complex molecular and cellular cascade—from a single therapeutic event to a vision-threatening structural catastrophe—occurred in less than two months, highlighting the fulminant and devastating potential of this pathologic process.[20]

This case provides a valuable platform for a critical evaluation of the clinical decisions made at each stage, offering insights into risk stratification, therapeutic alternatives, and surgical nuances. In retrospect, a crucial question is whether there were baseline features that hinted at this patient's predisposition to a severe post-laser inflammatory response. The presence of a large, bulky, multi-quadrant area of exudation and significant vitreous cholesterolosis could be interpreted as signs of a high-turnover, chronic inflammatory state. These features may indicate a retina already primed with a high load of macrophages and other inflammatory mediators, making it more susceptible to a dysregulated and exaggerated response when challenged with the acute inflammatory stimulus of laser.[18] While not definitive, these findings may constitute relative risk factors. Their presence should prompt clinicians to engage in a more detailed discussion with the patient about the heightened risk of post-treatment exacerbation and to consider alternative or adjunctive therapies. Furthermore, it argues for scheduling more frequent and vigilant post-treatment follow-up, with a low threshold for early intervention at the first sign of trouble. Given the potential for a post-laser inflammatory surge, a key question is whether this complication could have been mitigated or prevented. A strategy of "cooling down" the eye with anti-inflammatory or anti-permeability agents prior to applying a destructive thermal therapy is an attractive and logical concept.[19] This could involve pre-treatment with one or more intravitreal injections of an anti-VEGF agent. By reducing vascular permeability, decreasing edema, and potentially downregulating some inflammatory pathways, anti-VEGF therapy might have created a less reactive environment, possibly blunting the subsequent response to laser. Similarly, the use of intravitreal or sub-Tenon's corticosteroids, with their broad and potent anti-inflammatory properties, either before or concurrently with laser, could theoretically suppress the cytokine storm that drives the fibrotic cascade. While combination therapies are increasingly used in clinical practice, their precise role and timing in adult-onset Coats' disease are not yet defined by large-scale trials, and this case underscores the urgent need for research in this area. The choice of laser modality itself is also a factor worthy of discussion. The argon green laser (532nm) used here has significant absorption by melanin in the RPE but also causes considerable collateral thermal spread to the inner retinal layers. A 577nm yellow laser, with its higher absorption by hemoglobin and lower absorption by macular xanthophyll, might have allowed for more targeted treatment of the telangiectasias with less collateral thermal damage, potentially reducing the inflammatory footprint. An even more intriguing alternative would be photodynamic therapy (PDT) with verteporfin, a non-thermal modality that selectively induces thrombosis in abnormal vessels without significant thermal damage to the overlying retina, which could theoretically carry a much lower risk of inducing a fibrotic response.

Once the tractional retinal detachment was established and progressing towards the fovea, the decision for surgical intervention was unequivocal and urgent. Medical management is futile against the powerful mechanical forces of an organized, contracted fibrotic membrane. The surgical strategy employed was both comprehensive and elegant, addressing every aspect of the complex pathology.[20] The decision to peel not only the ERM but also the ILM was a critical and sophisticated surgical choice. While the ERM is the primary source of the traction, the ILM is the scaffold upon which it forms. Removing the ILM eliminates this scaffold, drastically reducing the risk of post-operative recurrence of fibrosis—a known and feared complication of such surgeries, especially in eyes with a demonstrated propensity for aggressive proliferation. This choice reflects a surgical philosophy aimed not just at repairing the immediate problem but also at ensuring long-term anatomical stability.The choice of peripheral cryotherapy over endolaser also warrants thoughtful consideration. Cryotherapy, a trans-scleral freezing therapy, induces a more intense and widespread inflammatory response than endolaser but creates an exceptionally strong and broad chorioretinal adhesion. In this case, given the patient had already demonstrated a profound fibrotic response to inflammation, this choice might seem counterintuitive. However, the surgeon likely reasoned that, with the vitreous (the reservoir of cytokines) and all membranes (the source of traction) removed, the primary drivers of proliferation were gone. The paramount goal at that stage was to create an unbreakably strong peripheral adhesion to prevent any future exudative or rhegmatogenous detachment in the treated area. Finally, the ability to achieve a successful outcome without the need for an internal tamponade agent like silicone oil or gas is the hallmark of a successful vitrectomy for tractional detachment. It signifies that all anteroposterior and tangential tractional forces were so completely and meticulously relieved that the retina could lie flat on its own, held in place only by the RPE pump and the newly formed chorioretinal adhesions. This represents the ideal anatomical outcome in such complex cases.



Figure 7. Pathophysiology of iatrogenic tractional retinal detachment.

Figure 7 showed a concise yet comprehensive schematic that masterfully illustrates the proposed pathophysiological cascade responsible for the development of an iatrogenic tractional retinal detachment (TRD) following laser therapy in the context of adult-onset Coats' disease. This four-stage visual narrative provides a framework for understanding the complex transition from a chronic, stable exudative vasculopathy to an acute, vision-threatening fibro-proliferative crisis. The figure distills a highly complex series of molecular and cellular events into a logical, sequential progression, offering profound insight into the clinical journey of the patient in this report. By exploring each stage in detail, we can build a deeper appreciation for the delicate biological equilibrium within the retina and the potentially devastating consequences when that balance is disrupted by therapeutic intervention. The first panel of the figure, "Baseline Coats' Disease," poignantly captures the fundamental, underlying pathology of this condition. The schematic depicts an abnormal retinal vessel, correctly highlighting the two key defects: a notable deficiency of pericytes and the resultant leakage of exudates. This simple graphic represents a complex and chronic state of contained vascular failure that defines the adult-onset variant of the disease. The pericyte, a mural cell that wraps around the endothelial cells of capillaries, is the unsung hero of the microvasculature. These cells are critical for maintaining the structural integrity, stability, and proper function of the blood-retinal barrier (BRB). They communicate directly with endothelial cells through peg-and-socket junctions, regulating blood flow, controlling endothelial cell proliferation, and reinforcing the tight junctions that form the crux of the inner BRB. In Coats' disease, there is a profound, albeit often localized, loss of these essential cells. The etiology of this pericyte dropout remains a subject of investigation. In pediatric cases, somatic mutations in the NDP gene, which disrupts the Norrin/Wnt signaling pathway essential for vascular maturation, are a known cause. In adults, the cause may be more varied, potentially involving a later-in-life somatic mutation, a localized degenerative process, or a chronic, low-grade inflammatory vasculopathy that selectively targets these cells. Regardless of the cause, the consequence is the same: the endothelial tube is left unsupported and dysfunctional.

Without the stabilizing influence of pericytes, the retinal capillaries become weak and prone to forming saccular and fusiform dilatations—the characteristic telangiectasias and "light-bulb" aneurysms. These abnormal vessels are functionally incompetent. Their endothelial tight junctions become compromised, leading to a chronic, slow breakdown of the inner BRB. This allows for the persistent, unchecked leakage of plasma constituents from the bloodstream into the retinal tissue and the subretinal space. This extravasated fluid is not merely water; it is a rich soup of proteins (like albumin), electrolytes, and, most importantly, lipids and lipoproteins. The accumulation of this lipid-rich fluid is what gives rise to the classic clinical sign of Coats' disease: the dense, yellow, waxy subretinal exudates. Over time, as this exudate persists, it is acted upon by retinal macrophages. These macrophages phagocytose the lipid material, becoming engorged "foam cells" and releasing inflammatory mediators that contribute to a chronic, low-grade inflammatory state. The breakdown of lipoproteins by these cells results in the precipitation of cholesterol crystals, which are seen clinically as glistening, refractile bodies within the vitreous (cholesterolosis) and subretinal space, as was observed in our patient. In the adult-onset form of the disease, this entire process is typically indolent and geographically confined. The areas of pericyte loss are often limited to one or two quadrants of the peripheral retina, leaving the remaining vasculature, including the critical macular circulation, intact. This is why patients, like the one in this report, can present with extensive peripheral pathology while maintaining excellent central vision of 20/20. The eye exists in a state of chronic, but contained, vascular failure. The baseline condition is a precarious equilibrium, where the slow rate of leakage is roughly balanced by the eye's ability to clear the fluid, preventing a rapid progression towards a total exudative detachment. It is upon this seemingly stable, yet fundamentally fragile, state that the therapeutic intervention is introduced. The second panel, "The Laser Paradox," illustrates the pivotal event in this pathophysiological drama: the application of laser photocoagulation. The graphic, showing a laser beam directed at the retina, symbolizes a therapeutic action that, in this specific biological context, had an unintended and catastrophic iatrogenic consequence. This stage represents the conversion of a therapeutic energy into a potent, pathological trigger that awakens a dormant cellular machinery of fibrosis. Laser photocoagulation is a cornerstone of retinal therapy. The principle is to use focused light energy to create a controlled thermal burn. In the treatment of Coats' disease, the goals are twofold: first, to directly coagulate and thrombose the leaking telangiectatic vessels, thereby sealing the source of the leakage; and second, to stimulate the surrounding RPE to proliferate and form a strong chorioretinal adhesion, which enhances the outer BRB and helps in the absorption of existing fluid. In the vast majority of cases, this controlled destruction leads to a positive therapeutic outcome. However, the term "controlled destruction" is key. The laser does not simply "fix" the vessels; it induces coagulative necrosis of the RPE, the photoreceptors, and the inner retinal layers at the site of application. This acute tissue injury is a powerful biological signal that initiates an immediate and intense wound-healing response. In a healthy eye, this response is well-regulated, leading to a stable, atrophic scar. However, in an eye already compromised by the chronic inflammation and vascular instability of Coats' disease, this wound-healing response can become dangerously dysregulated and exaggerated. This is the essence of the Laser Paradox. The very act designed to stop leakage and reduce inflammation instead triggers a massive, overwhelming inflammatory cascade. The thermal injury causes an immediate and massive release of pro-inflammatory mediators from the damaged retinal cells. This includes a host of powerful cytokines and growth factors, transforming the local retinal environment from one of chronic, low-grade inflammation to one of acute, high-intensity inflammation. This sudden and dramatic shift in the molecular milieu is the critical event that propels the disease from the stable exudative state of Stage 1 into the aggressive, proliferative state of Stage 3. The laser, therefore, acts not as a treatment in this case, but as the inciting incident, the spark that ignites a much larger fire. The third panel, "Cellular Activation & Fibrosis," is the mechanistic heart of the entire process. It graphically depicts the two core components of this stage: the "cytokine storm" and the subsequent activation and transformation of resident retinal cells into pro-fibrotic myofibroblasts. This panel explains how the thermal injury from the laser is translated into the biological machinery of scar formation. The Cytokine Storm: Immediately following the laser burn, the damaged retinal tissue releases a torrent of signaling molecules. Vascular endothelial growth factor (VEGF): While already present in Coats' disease, its levels are massively upregulated by the hypoxia and inflammation of the laser burn. VEGF is a potent vascular permeability factor. This sudden spike in VEGF overwhelms the retinal vasculature, causing a dramatic increase in leakage, which explains the clinical finding of worsened exudation and macular edema in our patient at the one-month follow-up. Transforming growth factor-beta (TGF-β): This is arguably the master regulator of fibrosis in the body. Released by damaged cells and infiltrating macrophages, TGF-β is the primary signal that initiates the fibrotic cascade. It directly activates the retinal cells responsible for scar formation. Tumor necrosis factor-alpha (TNF-α) and Interleukin-6 (IL-6): These are powerful pro-inflammatory cytokines that amplify the inflammatory response. They increase vascular leakage, promote the recruitment of more inflammatory cells, and contribute to the overall pro-fibrotic environment. Cellular Activation and Myofibroblastic Transformation: This intense cytokine soup acts upon the resident cells of the retina, primarily the Müller glial cells and the RPE cells. As depicted in the schematic, these cells are transformed into myofibroblasts. Müller Cells: These are the principal glial cells of the retina, providing structural and metabolic support. In response to injury and stimulation by TGF-β, they undergo a process called reactive gliosis. They become hypertrophic and proliferative, but most importantly, they undergo a myofibroblastic transdifferentiation. They begin to produce α-smooth muscle actin (α-SMA), a contractile protein, and they switch their synthetic machinery to produce massive quantities of extracellular matrix (ECM) proteins, such as collagen and fibronectin. RPE Cells: The RPE cells, directly damaged by the laser, can undergo a similar transformation through a process called epithelial-mesenchymal transition (EMT). They lose their stable, epithelial characteristics and become migratory, proliferative, fibroblast-like cells that also produce contractile proteins and ECM. These newly formed myofibroblasts are the cellular engines of fibrosis. They are mobile, contractile, and relentlessly secrete ECM proteins. They migrate onto the retinal surfaces, particularly the inner retinal surface, using the internal limiting membrane (ILM) as a natural scaffold. Here, they continue to proliferate and lay down a dense, avascular, and contractile sheet of scar tissue. This sheet is the biological entity known as the epiretinal membrane (ERM). Stage 3, therefore, represents the crucial biological switch where the initial inflammatory response to the laser is successfully converted into a full-blown, cellular-driven fibrotic process. The final panel, "TRD Formation," illustrates the devastating mechanical end-point of this entire cascade. It shows the fully formed ERM contracting and physically pulling the retina away from the underlying RPE, causing a tractional retinal detachment. This is the ultimate structural failure of the retina, directly resulting from the preceding biological events. The epiretinal membrane formed in Stage 3 is not a static scar. It is a dynamic, living tissue populated by contractile myofibroblasts. Over weeks to months, these cells exert a slow, powerful, and relentless contractile force. This force is transmitted across the entire membrane and, consequently, across the surface of the retina to which it is adhered. This is known as tangential traction. Initially, this traction may only cause a subtle wrinkling of the retinal surface, leading to the symptom of metamorphopsia (distorted vision). However, as the contraction continues and the membrane becomes stiffer and stronger, the force becomes sufficient to overcome the natural forces holding the retina in place (such as the RPE pump and the intraocular pressure). The membrane begins to physically lift the full thickness of the sensory retina off the underlying RPE. This is a tractional retinal detachment (TRD). The schematic accurately depicts this process: a dark, contractile line (the ERM) on the surface of the retina, which is tented up and separated from the basal layer (the RPE). The space created beneath the detached retina can then fill with subretinal fluid, further propagating the detachment. As was seen in our patient, this process can be alarmingly rapid, progressing from an initial ERM at one month to a frank TRD threatening the fovea by the second month. Once a TRD has formed, the condition is no longer treatable with medical or laser therapy. The problem is now purely mechanical. The only solution is to surgically intervene to physically cut and peel the contractile membrane from the retinal surface, thereby relieving the traction and allowing the retina to settle back into its proper position. Stage 4, therefore, represents the culmination of the pathophysiological journey—a journey that started with a single therapeutic laser burn and ended with a complex surgical emergency. The figure, in its entirety, serves as a powerful and essential teaching tool, providing a clear and logical explanation for a rare but devastating iatrogenic complication in ophthalmology.

4. Conclusion

This case report chronicles a journey from a seemingly straightforward diagnosis to a complex surgical challenge, offering a powerful lesson in the potential dual nature of retinal therapies. It demonstrates with sobering clarity that laser photocoagulation, a cornerstone of management for Coats' disease, can precipitate a devastating inflammatory and fibrotic cascade, rapidly converting a stable exudative condition into an acute surgical crisis. This report illuminates the critical transition from an exudative to a tractional pathophysiology and mandates that clinicians maintain a high index of suspicion for this complication, employing vigilant, multimodally-imaged surveillance after any ablative procedure. Ultimately, this case argues for a paradigm shift in managing complex adult-onset Coats' disease. It highlights the need to risk-stratify patients and consider combination therapies to mitigate inflammation. Most importantly, it confirms that when confronted with the mechanical reality of iatrogenic fibrosis, a timely transition from retinal-based therapies to definitive vitreoretinal surgery is not merely an option but an essential strategy. It is through such decisive surgical intervention that we can navigate these profound therapeutic challenges, converting a path of irreversible vision loss into one of anatomical restoration and meaningful functional recovery.

5. References

1. Ledesma-Gil G, Moreno Andrade AB, Shields CL. Secondary vasoproliferative tumor in adult-onset Coats disease. Can J Ophthalmol. 2022; 57(1): 69–70.
2. Banerjee M, Nayak S, Kumar S, Bhayana AA, Kumar V. Adult-onset Coats disease. Surv Ophthalmol. 2023; 68(4): 591–600.
3. Kim HU, Shin SH, Park SP. Intravitreal ranibizumab injection in adult-onset coats' disease: a case report. J Korean Ophthalmol Soc. 2017; 58(7): 870.
4. Kumar V, Kumar P. Vitrectomy for epiretinal membrane in adult-onset Coats' disease. Indian J Ophthalmol. 2017; 65(10): 1046.
5. Kumar V, Kumar P, Garg G, Damodaran S. Vitrectomy for full-thickness macular hole in adult-onset Coats' disease. Indian J Ophthalmol. 2017; 65(11): 1246–8.
6. Sakurada Y, Freund KB, Yannuzzi LA. Multimodal imaging in adult-onset coats' disease. Ophthalmology. 2018; 125(4): 485.
7. Kumar K, Raj P, Chandnani N, Agarwal A. Intravitreal dexamethasone implant with retinal photocoagulation for adult-onset Coats' disease. Int Ophthalmol. 2019; 39(2): 465–70.
8. Bottini A, Yuan A, Singh RP, Lee G, Dedania V, Modi YS. Multimodal imaging of adult-onset Coats' disease. Am J Ophthal Clin Trials. 2019; 2(3): 3.

9. Das M, Chaudhary P, Varshney A. Microincision vitrectomy for secondary epiretinal membrane in adult-onset Coats' disease. Delhi J Ophthalmol. 2019; 30(1): 49–51.
10. Elnahry AG, Sallam EM, Guirguis KJ, Talbet JH, Abdel-Kader AA. Vitrectomy for a secondary epiretinal membrane following treatment of adult-onset Coats' disease. Am J Ophthalmol Case Rep. 2019; 15(100508): 100508.
11. Wang Y, Fan H, Gao K, He W, Tao Y. Levels of cytokines in the aqueous humor guided treatment of refractory macular edema in adult-onset coats' disease. BMC Ophthalmol. 2020; 20(1): 261.
12. Alsaggaf K, Jalloun M, Alkhotani W, Albeedh M. Three-year results of management of adult-onset Coats' disease by possibly targeting placental growth factor. Cureus. 2020; 12(9): e10652.
13. Xu X, Essilfie J, Gong Y, Yu S-Q, Freund KB. Resolution of foveal lipid deposition in adult-onset Coats disease with combined focal laser photocoagulation and anti-VEGF therapy. Ophthalmic Surg Lasers Imaging Retina. 2021; 52(7): 396–9.
14. Plaza-Laguardia C, Pascual-Camps I, Bayón-Porras MR, Sánchez-Cañizal J, Gallego-Pinazo R. Intravitreal ranibizumab injection and retinal laser photocoagulation treatment for adult-onset coats disease. Retin Cases Brief Rep. 2021; 15(5): 532–5.
15. Mustafi D, Stacey AW. Unilateral peripheral vascular retinal disease associated with a developmental arcade vessel anomaly in adult-onset Coats' disease. Am J Ophthalmol Case Rep. 2022; 25(101408): 101408.
16. Dave AD, Thavikulwat AT, De Silva T, Wiley HE, Keenan TDL, Wong WT, et al. Longitudinal characterization and treatment response of retinal arterial macroaneurysms in adult-onset coats disease. Am J Ophthalmol Case Rep. 2022; 27(101647): 101647.
17. Sindal MD, Vaidya MV, Sivaranjani S. The leaky light bulbs of adult-onset coats' disease – Multimodal imaging. Indian J Ophthalmol Case Rep. 2023; 3(3): 962–962.
18. Zhou W, Zhou H, Liu Y-Y, Li M-X, Wu X-H, Liang J, et al. Multimodal imaging diagnosis and analysis of prognostic factors in patients with adult-onset Coats disease. Int J Ophthalmol. 2024; 17(8): 1469–76.
19. Ku CA, Lema GM. Efficacy of aflibercept in bevacizumab-resistant macular edema in adult-onset Coats disease. J Vitreoretin Dis. 2019; 3(6): 480–4.
20. Hansraj S, Raval V, Jalali S, Sahoo N, Das AV. Clinical presentation and treatment outcomes of adult-onset Coats disease. J Vitreoretin Dis. 2024; 24741264241286580.